share_log

bluebird bio | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-BlackRock, Inc.(4.7%)

bluebird bio | SC 13G/A:超過5%持股股東披露文件(修正)-BlackRock, Inc.(4.7%)

SEC announcement ·  01/08 00:00
Moomoo AI 已提取核心訊息
BlackRock, Inc., a major investment management corporation based in Delaware, has filed an amended Schedule 13G with the Securities and Exchange Commission on January 8, 2024, indicating a change in its holdings in bluebird bio, a biotechnology company. The filing, dated December 31, 2023, shows that BlackRock now beneficially owns 8,983,001 shares of bluebird bio's common stock, which represents 4.7% of the company's class of securities. This marks a decrease in ownership, as BlackRock has checked the box indicating that it has ceased to be the beneficial owner of more than 5 percent of the class of securities. The filing also details that BlackRock has sole voting power over 8,832,224 shares and sole dispositive power over all 8,983,001 shares it owns. The address of bluebird bio's principal executive offices is listed as 455 Grand Union Boulevard, Somerville, MA 02145.
BlackRock, Inc., a major investment management corporation based in Delaware, has filed an amended Schedule 13G with the Securities and Exchange Commission on January 8, 2024, indicating a change in its holdings in bluebird bio, a biotechnology company. The filing, dated December 31, 2023, shows that BlackRock now beneficially owns 8,983,001 shares of bluebird bio's common stock, which represents 4.7% of the company's class of securities. This marks a decrease in ownership, as BlackRock has checked the box indicating that it has ceased to be the beneficial owner of more than 5 percent of the class of securities. The filing also details that BlackRock has sole voting power over 8,832,224 shares and sole dispositive power over all 8,983,001 shares it owns. The address of bluebird bio's principal executive offices is listed as 455 Grand Union Boulevard, Somerville, MA 02145.
總部位於特拉華州的大型投資管理公司貝萊德公司已於2024年1月8日向美國證券交易委員會提交了經修訂的附表13G,表明其對生物技術公司藍鳥生物的持股發生了變化。這份日期爲2023年12月31日的文件顯示,貝萊德現在實益擁有藍鳥生物普通股的8,983,001股,佔該公司證券類別的4.7%。這標誌着所有權的減少,因爲貝萊德已經勾選了表明其已不再是該類別5%以上證券的受益所有人的複選框。該文件還詳細說明,貝萊德擁有對8,832,224股股票的唯一投票權,對其擁有的所有8,983,001股股票擁有唯一的處置權。bluebird bio的主要行政辦公室地址被列爲馬薩諸塞州薩默維爾大道455號02145。
總部位於特拉華州的大型投資管理公司貝萊德公司已於2024年1月8日向美國證券交易委員會提交了經修訂的附表13G,表明其對生物技術公司藍鳥生物的持股發生了變化。這份日期爲2023年12月31日的文件顯示,貝萊德現在實益擁有藍鳥生物普通股的8,983,001股,佔該公司證券類別的4.7%。這標誌着所有權的減少,因爲貝萊德已經勾選了表明其已不再是該類別5%以上證券的受益所有人的複選框。該文件還詳細說明,貝萊德擁有對8,832,224股股票的唯一投票權,對其擁有的所有8,983,001股股票擁有唯一的處置權。bluebird bio的主要行政辦公室地址被列爲馬薩諸塞州薩默維爾大道455號02145。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息